Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Edgewise Therapeutics (Nasdaq:EWTX) granted inducement stock options on June 30, 2026 to 2 new non-executive employees under its 2024 Inducement Equity Incentive Plan.

Rhea-AI Summary

Edgewise Therapeutics (Nasdaq:EWTX) granted inducement stock options on June 30, 2026 to 2 new non-executive employees under its 2024 Inducement Equity Incentive Plan.

The options cover 16,500 shares at an exercise price of $40.63 per share and vest over four years, consistent with Nasdaq Listing Rule 5635(c)(4).

Argus Jul 1 session

-3.64% close to close Open Argus

Details

News Market Reaction – EWTX

In the Jul 1 session, EWTX declined 3.64%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details options for 16,500 shares at $40.63, a standard hiring tool under Nasdaq r...

Analysis

This announcement details options for 16,500 shares at $40.63, a standard hiring tool under Nasdaq rules. Against recent major strategic news and insider net selling, investors may watch how ongoing equity grants and governance trends evolve.

Key Figures

Inducement option grant size: 16,500 shares Employees receiving grants: 2 employees Exercise price: $40.63 per share +4 more

Inducement option grant size

16,500 shares

Stock options to 2 new non-executive employees under 2024 Inducement Plan

Employees receiving grants

2 employees

New non-executive hires receiving inducement stock options

Exercise price

$40.63 per share

Equal to EWTX closing price on June 30, 2026 grant date

Initial vesting tranche

25% of shares

Vests on one-year anniversary of each employee’s start date

Ongoing vesting rate

1/48th monthly

Remaining option shares vest monthly after the first anniversary

Inducement plan year

2024

Edgewise 2024 Inducement Equity Incentive Plan governing these awards

Nasdaq rule reference

Rule 5635(c)(4)

Grants made as inducement awards under Nasdaq Listing Rules

Historical Context

5 past events · Latest: Jun 16

5 events

1. Jun 16

   Clinical trial update

   24h Move

   -3.6%

   Positive 12-week Phase 2 CIRRUS-HCM data for EDG-7500 in HCM patients.

2. Jun 03

   Equity compensation

   24h Move

   +2.8%

   Inducement stock options granted to new employees under 2024 Inducement Plan.

3. Jun 01

   Business sale agreement

   24h Move

   +17.9%

   Servier agreement to acquire muscular dystrophy business for up to $2.65B.

4. Jun 01

   Strategic refocus

   24h Move

   +17.9%

   Sale of sevasemten to Servier to strengthen balance sheet and focus on CV pipeline.

5. May 12

   Conference appearance

   24h Move

   -1.6%

   Announcement of presentation at RBC Capital Markets Global Healthcare Conference.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

inducement stock options, inducement equity incentive plan, exercise price, nasdaq listing rule 5635(c)(4)

4 terms

inducement stock options financial

"Edgewise granted inducement stock options to purchase a total of 16,500 shares"

Inducement stock options are grants of the company’s stock rights given to recruit or retain a specific executive or employee, often as a signing bonus instead of cash. Investors care because these awards can increase the total shares outstanding and dilute existing ownership, alter future reported expenses, and signal how the company is paying for talent; think of them as a hiring incentive paid in future company pieces rather than immediate money.

inducement equity incentive plan financial

"pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan")"

An inducement equity incentive plan is a program that grants employees or executives company shares or stock options to motivate and reward their work, often as a way to attract new talent. It aligns their interests with the company's success, encouraging them to contribute to long-term growth. For investors, such plans can influence a company's stock performance and overall financial health by motivating key personnel.

exercise price financial

"Each inducement stock option has an exercise price of $40.63 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

nasdaq listing rule 5635(c)(4) regulatory

"were granted as inducements ... in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOULDER, Colo., July 1, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on June 30, 2026, Edgewise granted inducement stock options to purchase a total of 16,500 shares of Edgewise's common stock to 2 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").

Each inducement stock option has an exercise price of $40.63 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.

Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4). 

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: edgewisetx.com or follow us on LinkedIn, X , Facebook and Instagram.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302815397.html

SOURCE Edgewise Therapeutics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement stock options did Edgewise Therapeutics (EWTX) grant on June 30, 2026?

Edgewise Therapeutics granted inducement stock options for a total of 16,500 common shares to two new non-executive employees. According to Edgewise, these options were issued under the 2024 Inducement Equity Incentive Plan as material inducements to join the company.

What is the exercise price of the new Edgewise Therapeutics (EWTX) inducement options?

The inducement stock options have an exercise price of $40.63 per share. According to Edgewise, this price equals the closing price of its common stock on the June 30, 2026 grant date, aligning the awards with then-current market value.

How do the Edgewise Therapeutics (EWTX) inducement options granted in June 2026 vest?

The inducement options vest over four years. According to Edgewise, 25% vests on each employee’s one-year employment anniversary, with the remaining 75% vesting in equal monthly installments (1/48th) thereafter, subject to continued service.

Why were the June 30, 2026 Edgewise Therapeutics (EWTX) options classified as inducement grants?

They qualify as inducement grants because they were provided as material incentives for two new employees to join Edgewise. According to Edgewise, the awards comply with Nasdaq Listing Rule 5635(c)(4) and are issued under the 2024 Inducement Equity Incentive Plan.

How many employees received Edgewise Therapeutics (EWTX) inducement options in June 2026?

Two new non-executive employees received inducement stock options on June 30, 2026. According to Edgewise, the total award covers 16,500 common shares, allocated between these hires in connection with the start of their employment.

Under which equity plan were the June 30, 2026 Edgewise Therapeutics (EWTX) inducement options granted?

The options were granted under the company’s 2024 Inducement Equity Incentive Plan. According to Edgewise, each award is subject to the plan’s terms and related agreements, governing vesting, exercise, and other key conditions.